Navigation Links
Acute Myeloid Leukemia Drugs Price Analysis and Strategies 2012-2016 & Forecasts to 2021 - Research and Markets
Date:3/1/2017

DUBLIN, Mar 01, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Acute Myeloid Leukemia Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Acute Myeloid Leukemia Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Acute Myeloid Leukemia market.

This research will help executives identify clinical attributes of your competitor drugs and find out how the marketed products for Acute Myeloid Leukemia are clinically and commercially positioned. It will help the reader understand the price of your competitor drugs by countries. The report will also reveal the pricing and reimbursement landscape by countries as well as identify the unmet need in global Acute Myeloid Leukemia market

The research answers the following questions:

  • What are the key drugs marketed for Acute Myeloid Leukemia and their clinical attributes? How are they positioned in the Global Acute Myeloid Leukemia market?
  • What are the unit prices and annual treatment cost for Acute Myeloid Leukemia therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Acute Myeloid Leukemia drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Acute Myeloid Leukemia?

Research Scope:

  • Acute Myeloid Leukemia Treatment Options - Identify key drugs marketed and prescribed for Acute Myeloid Leukemia in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Acute Myeloid Leukemia Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Acute Myeloid Leukemia
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Acute Myeloid Leukemia market
  • Acute Myeloid Leukemia Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Acute Myeloid Leukemia in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Acute Myeloid Leukemia New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

Key Topics Covered:

1. Acute Myeloid Leukemia Treatment Options

2. Acute Myeloid Leukemia Drugs Clinical Attributes

3. Acute Myeloid Leukemia Drugs Market Positioning

4. Acute Myeloid Leukemia Drugs Price Analysis

5. Acute Myeloid Leukemia Drugs Price Benchmarks

6. Drug Pricing & Reimbursement Landscape

7. Acute Myeloid Leukemia Drugs Price Forecast

8. Acute Myeloid Leukemia Market Unmet Needs

9. Acute Myeloid Leukemia New Drug Pricing

For more information about this report visit http://www.researchandmarkets.com/research/z4rf2q/acute_myeloid

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acute-myeloid-leukemia-drugs-price-analysis-and-strategies-2012-2016--forecasts-to-2021---research-and-markets-300415820.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Novartiss Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
2. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
3. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
4. Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
5. CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
6. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
7. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
8. Systematic Review Finds Intranasal Midazolam Comparable To Intravenous Or Rectal Administration Of Diazepam For Treatment Of Acute Seizure Emergencies In Pediatric Patients
9. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
10. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
11. Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... ... 2017 , ... The Military Officers Association of America (MOAA) announced its support ... retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the staff director ... with the issues and challenges veterans face with the VA. Following a 30-year career ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening ... 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned ... owns three other locations in the Topeka and Bonner Springs, Kan. area. , ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South ... selected 21 leaders from government, business and civil society in 11 countries across the ... this fall, engaging in a transformative exchange of knowledge and ideas with the leading ...
Breaking Medicine News(10 mins):